Inhibiting glycogen synthesis prevents lafora disease in a mouse model

Bartholomew A. Pederson, Julie Turnbull, Jonathan R. Epp, Staci A. Weaver, Xiaochu Zhao, Nela Pencea, Peter Roach, Paul W. Frankland, Cameron A. Ackerley, Berge A. Minassian

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Lafora disease (LD) is a fatal progressive myoclonus epilepsy characterized neuropathologically by aggregates of abnormally structured glycogen and proteins (Lafora bodies [LBs]), and neurodegeneration. Whether LBs could be prevented by inhibiting glycogen synthesis and whether they are pathogenic remain uncertain. We genetically eliminated brain glycogen synthesis in LD mice. This resulted in long-term prevention of LB formation, neurodegeneration, and seizure susceptibility. This study establishes that glycogen synthesis is requisite for LB formation and that LBs are pathogenic. It opens a therapeutic window for potential treatments in LD with known and future small molecule inhibitors of glycogen synthesis.

Original languageEnglish
Pages (from-to)297-300
Number of pages4
JournalAnnals of Neurology
Volume74
Issue number2
DOIs
StatePublished - Aug 2013

Fingerprint

Lafora Disease
Glycogen
Progressive Myoclonic Epilepsy
Seizures
Brain
Proteins

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Pederson, B. A., Turnbull, J., Epp, J. R., Weaver, S. A., Zhao, X., Pencea, N., ... Minassian, B. A. (2013). Inhibiting glycogen synthesis prevents lafora disease in a mouse model. Annals of Neurology, 74(2), 297-300. https://doi.org/10.1002/ana.23899

Inhibiting glycogen synthesis prevents lafora disease in a mouse model. / Pederson, Bartholomew A.; Turnbull, Julie; Epp, Jonathan R.; Weaver, Staci A.; Zhao, Xiaochu; Pencea, Nela; Roach, Peter; Frankland, Paul W.; Ackerley, Cameron A.; Minassian, Berge A.

In: Annals of Neurology, Vol. 74, No. 2, 08.2013, p. 297-300.

Research output: Contribution to journalArticle

Pederson, BA, Turnbull, J, Epp, JR, Weaver, SA, Zhao, X, Pencea, N, Roach, P, Frankland, PW, Ackerley, CA & Minassian, BA 2013, 'Inhibiting glycogen synthesis prevents lafora disease in a mouse model', Annals of Neurology, vol. 74, no. 2, pp. 297-300. https://doi.org/10.1002/ana.23899
Pederson BA, Turnbull J, Epp JR, Weaver SA, Zhao X, Pencea N et al. Inhibiting glycogen synthesis prevents lafora disease in a mouse model. Annals of Neurology. 2013 Aug;74(2):297-300. https://doi.org/10.1002/ana.23899
Pederson, Bartholomew A. ; Turnbull, Julie ; Epp, Jonathan R. ; Weaver, Staci A. ; Zhao, Xiaochu ; Pencea, Nela ; Roach, Peter ; Frankland, Paul W. ; Ackerley, Cameron A. ; Minassian, Berge A. / Inhibiting glycogen synthesis prevents lafora disease in a mouse model. In: Annals of Neurology. 2013 ; Vol. 74, No. 2. pp. 297-300.
@article{1b38764ebfd84dc29ca9dfa29616cf63,
title = "Inhibiting glycogen synthesis prevents lafora disease in a mouse model",
abstract = "Lafora disease (LD) is a fatal progressive myoclonus epilepsy characterized neuropathologically by aggregates of abnormally structured glycogen and proteins (Lafora bodies [LBs]), and neurodegeneration. Whether LBs could be prevented by inhibiting glycogen synthesis and whether they are pathogenic remain uncertain. We genetically eliminated brain glycogen synthesis in LD mice. This resulted in long-term prevention of LB formation, neurodegeneration, and seizure susceptibility. This study establishes that glycogen synthesis is requisite for LB formation and that LBs are pathogenic. It opens a therapeutic window for potential treatments in LD with known and future small molecule inhibitors of glycogen synthesis.",
author = "Pederson, {Bartholomew A.} and Julie Turnbull and Epp, {Jonathan R.} and Weaver, {Staci A.} and Xiaochu Zhao and Nela Pencea and Peter Roach and Frankland, {Paul W.} and Ackerley, {Cameron A.} and Minassian, {Berge A.}",
year = "2013",
month = "8",
doi = "10.1002/ana.23899",
language = "English",
volume = "74",
pages = "297--300",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Inhibiting glycogen synthesis prevents lafora disease in a mouse model

AU - Pederson, Bartholomew A.

AU - Turnbull, Julie

AU - Epp, Jonathan R.

AU - Weaver, Staci A.

AU - Zhao, Xiaochu

AU - Pencea, Nela

AU - Roach, Peter

AU - Frankland, Paul W.

AU - Ackerley, Cameron A.

AU - Minassian, Berge A.

PY - 2013/8

Y1 - 2013/8

N2 - Lafora disease (LD) is a fatal progressive myoclonus epilepsy characterized neuropathologically by aggregates of abnormally structured glycogen and proteins (Lafora bodies [LBs]), and neurodegeneration. Whether LBs could be prevented by inhibiting glycogen synthesis and whether they are pathogenic remain uncertain. We genetically eliminated brain glycogen synthesis in LD mice. This resulted in long-term prevention of LB formation, neurodegeneration, and seizure susceptibility. This study establishes that glycogen synthesis is requisite for LB formation and that LBs are pathogenic. It opens a therapeutic window for potential treatments in LD with known and future small molecule inhibitors of glycogen synthesis.

AB - Lafora disease (LD) is a fatal progressive myoclonus epilepsy characterized neuropathologically by aggregates of abnormally structured glycogen and proteins (Lafora bodies [LBs]), and neurodegeneration. Whether LBs could be prevented by inhibiting glycogen synthesis and whether they are pathogenic remain uncertain. We genetically eliminated brain glycogen synthesis in LD mice. This resulted in long-term prevention of LB formation, neurodegeneration, and seizure susceptibility. This study establishes that glycogen synthesis is requisite for LB formation and that LBs are pathogenic. It opens a therapeutic window for potential treatments in LD with known and future small molecule inhibitors of glycogen synthesis.

UR - http://www.scopus.com/inward/record.url?scp=84884894346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884894346&partnerID=8YFLogxK

U2 - 10.1002/ana.23899

DO - 10.1002/ana.23899

M3 - Article

VL - 74

SP - 297

EP - 300

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -